318 related articles for article (PubMed ID: 22157572)
1. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
[TBL] [Abstract][Full Text] [Related]
2. Anterior segment uses of bevacizumab.
Bahar I; Yeung SN; Sella R; Slomovic A
Curr Opin Ophthalmol; 2012 Jul; 23(4):303-16. PubMed ID: 22634640
[TBL] [Abstract][Full Text] [Related]
3. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model.
Liarakos VS; Papaconstantinou D; Vergados I; Douvali M; Theodossiadis PG
Eur J Ophthalmol; 2014; 24(3):299-308. PubMed ID: 24242219
[TBL] [Abstract][Full Text] [Related]
4. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
5. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab (avastin) in ocular processes other than choroidal neovascularization.
Barkmeier AJ; Akduman L
Ocul Immunol Inflamm; 2009; 17(2):109-17. PubMed ID: 19412873
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
9. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
11. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
12. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
13. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
Benayoun Y; Adenis JP; Casse G; Forte R; Robert PY
Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
[TBL] [Abstract][Full Text] [Related]
14. Antivascular endothelial growth factors in anterior segment diseases.
Scholl S; Kirchhof J; Augustin AJ
Dev Ophthalmol; 2010; 46():133-139. PubMed ID: 20703039
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
Park JH; Joo CK; Chung SK
Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
[TBL] [Abstract][Full Text] [Related]
16. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
17. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
18. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.
Han YS; Lee JE; Jung JW; Lee JS
Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554
[TBL] [Abstract][Full Text] [Related]
20. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.
Su W; Li Z; Li Y; Lin M; Yao L; Liu Y; He Z; Wu C; Liang D
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):9108-15. PubMed ID: 22039247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]